AzTrials
AzTrials

Chronic PainH-PassionNCT07740681

Human Pain Atlas for Sensory Neurons

An observational study of Chronic Pain, run by King's College Hospital NHS Trust.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to improve our understanding of how the nerves that detect and transmit pain signals work in humans. Chronic pain affects millions of people worldwide and can be difficult to treat because the biological mechanisms underlying pain are not yet fully understood. Read more about this study

Who is it for?
Ages 18 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Chronic Pain
What is being tested?
Microneurography
How many people
200 participants
Where
No sites listed yet
Study dates
Sep 2026to Sep 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: 100 patients with ongoing neuropathic pain in the context of a possible small fibre neuropathy or C-fibre dysfunction. 100 healthy volunteers.

Who may be able to join

  • Between 18 and 75 years of age.
  • Male and female.
  • In the capacity to understand and sign an Informed Consent Form.
  • Willing and able to comply with scheduled visits and study procedures.
  • Criteria for chronic pain participants:
  • Ongoing neuropathic pain in the context of a possible small fibre neuropathy or C-fibre dysfunction
  • Criteria for healthy participants:
  • Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history and a full physical examination.

Who cannot join

  • Previous diagnosis of an established autoimmune condition or dermatological conditions affecting skin afferents (e.g. psoriasis, lupus, vitiligo, dermatitis…).
  • Application of local anaesthetics or steroid injections within 35 days prior to the microneurography visit.
  • Unsuitable anatomy of the superficial peroneal nerve (i.e. nerve cannot be seen or palpated at the dorsum of the foot/ankle)
  • Infection, disease (dermatologic or vascular), ongoing pain or recent trauma or surgery that may affect study assessments.
  • Current use of anticoagulant therapy.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Ana Ribeiro, MSc contact

+447768974020

anaribeiro@nhs.net

Jordi Serra, MD contact

jserra@nhs.net

About this study

Official title: Human Pain Atlas for Sensory Neurons: A Multimodal Strategy of Investigation of Neuropathic Pain MechanismsH-Passion

This study aims to improve our understanding of how the nerves that detect and transmit pain signals work in humans. Chronic pain affects millions of people worldwide and can be difficult to treat because the biological mechanisms underlying pain are not yet fully understood. By gaining a better understanding of the human pain system, this research may help guide the development of more effective and personalised treatments for chronic pain in the future.

The study will investigate sensory neurons, which are specialised nerve cells that detect sensations such as touch, temperature, and injury. We will examine both how these nerve cells respond to stimulation and the genes they express. By linking the activity of individual nerve cells with their molecular characteristics, we hope to identify specific types of sensory neurons that may contribute to chronic pain conditions.

Read more

To achieve this, we will use a technique called microneurography. This involves inserting a very fine recording electrode into a peripheral nerve to measure the activity of individual nerve fibres directly in the body. These recordings will be performed in healthy volunteers and in patients. The information obtained will be combined with laboratory-based studies conducted by collaborators in Germany and France, allowing us to relate detailed biological findings to the experience of pain in humans.

The results of this research will provide a detailed map of the human sensory nervous system and improve our understanding of how pain-signalling neurons function in health and disease. This knowledge may support the development of future treatments for chronic pain.

Read the detailed description

Chronic pain remains a major challenge for modern healthcare, with limited effective treatments. Neuropathic pain is linked to increased activity in pain-relevant subgroups of the sensory neurons located in the dorsal root ganglia. One of the key reasons for the lack of effective treatments is the incomplete understanding of the neurobiological mechanisms underlying chronic neuropathic pain, particularly in the context of human-specific pain pathways. While animal models have provided valuable insights, they do not fully recapitulate human pain experiences due to significant species differences, especially in the structure and function of sensory neurons, which has led to significant translational hurdles in the development of new pain therapies.

In recent years, research has made significant strides in creating transcriptomic atlases of sensory neurons. These atlases provide valuable insights into the genetic and molecular landscape of human nociceptors. However, they are often limited by the inability to fully link these molecular findings with functional data, especially in the context of chronic pain. Additionally, many of these atlases are based on limited data from healthy donors, thus not fully capturing the heterogeneity found in pain-related sensory neurons. While recent efforts have begun to address these gaps by exploring the relationship between transcriptomic data and sensory neuron function, the field still faces major limitations. One key issue is the identification of pain-related sensory neurons, which can exhibit diverse activity patterns that may not align with current classifications. Moreover, existing atlases lack the integration of long-read RNA sequencing, which is crucial for identifying splice variants and other molecular nuances that may be critical for understanding pain pathways.

This consortium will leverage state-of-the-art technologies like Patch-Seq, single-cell long-read RNA sequencing, and microneurography to build a comprehensive atlas of human sensory neurons involved in pain processing. This approach will integrate high-resolution transcriptomic data with functional information, which is essential for addressing the current gap in our understanding of pain sensory neurons. One of the main challenges in the field has been the difficulty of linking molecular data to function, particularly when it comes to pain subtypes. The proposed project's approach will address this challenge by incorporating multiple techniques, which are expected to produce a more nuanced and clinically relevant understanding of sensory neuron diversity. Despite the promising progress made in creating human Dorsal Root Ganglia (DRG) atlases, the identification of pain-related neurons remains a significant challenge. There are concerns that certain pain-related neurons may not be captured using standard stimulation protocols. This is especially true for neurons whose activity patterns differ from known models. To address this, the proposal will combine detailed in-vitro and in-vivo electrophysiological recordings with advanced RNA sequencing to characterise sensory neurons, using stimulation protocols that are tailored to capture a wider range of neuronal subtypes. We will develop subtype-specific stimulation paradigms for in vivo microneurography as another innovative aspect of this proposal. This method could dramatically enhance our ability to stratify patients based on the specific sensory neuron subtypes contributing to their pain, thus facilitating personalised approaches to pain management. Moreover, integrating human tissue samples from both healthy and chronic pain patients is a significant step forward in ensuring that findings are potentially validated in a clinical scenario. This approach not only makes the project more clinically relevant but also enhances its translational potential since there is still a huge demand for novel pharmacological targets for pain treatment. With our consortium, we expect to identify novel sensory neuron-subtype specific transcript isoforms as biomarkers and druggable targets for e.g. gene therapeutic approaches like ASOs (antisense-oligonucleotides). By selectively targeting transcript isoforms that are specific to sensory neurons of chronic pain patients, ASO-mediated splice modulation that could change the amount of a "pathological" transcript isoform will be investigated in future follow-up studies as "genetic pain killers".

This project aims to fill the critical gap in the current understanding of pain-related sensory neurons by generating a comprehensive, multidimensional atlas of human sensory neurons. By combining the latest advances in transcriptomics, electrophysiology, and microneurography, the proposal promises to offer new insights into the molecular and functional diversity of sensory neurons involved in chronic pain. This integrated approach not only addresses existing knowledge gaps but also provides a solid foundation for future therapeutic advancements in pain management.

The main objective is to elucidate the molecular and functional mechanisms underlying chronic neuropathic pain by building the first comprehensive, multimodal sensory neuron atlas based on human DRG material. This dataset will integrate electrophysiology, gene expression (including long-read single-cell RNA sequencing), and in vivo microneurography data in humans, ultimately identifying novel molecular and electrophysiological biomarkers and neuronal subtypes involved in pain processing.

The UK organisation will be responsible for obtaining microneurography recordings from human participants, including patients suffering from chronic pain conditions and healthy volunteers, to refine neuron subtype classifications and develop new stimulation protocols. These will be used for refinement of the functional characterisation of neurons in the Patch-Seq Pipeline. This will end in a multimodal atlas of sensory neurons, with integration of long-read transcriptomic data with electrophysiological properties from Patch-seq and in vivo microneurography to classify pain-relevant neuronal subtypes.

Conditions
Chronic Pain
Being tested
Microneurography
Keywords
Chronic pain, Microneurography, Human Sensory Atlas
Medical subject headings
Chronic Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MicroneurographyDiagnostic test

    Electrophysiological technique that can record action potentials from individual peripheral nerve axons in humans. The test will be used to identify/rule out small nerve fibre dysfunction and measures of axonal excitability.

Study groups in NCT07740681
Study groupRoleWhat they receive
Chronic painParticipants suffering from chronic neuropathic pain.
Receives: Diagnostic Test: Microneurography
Healthy volunteersHealthy volunteers, defined by no clinically relevant abnormalities identified by a detailed medical history and a full physical examination.
Receives: Diagnostic Test: Microneurography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment of molecular and functional mechanisms underlying chronic neuropathic pain

    To refine neuron subtype classifications by developing new stimulation paradigms for precise classification of neuronal subgroups involved in chronic pain. To specify underlying mechanisms of the unmyelinated axonal membrane excitability.

    Measured: Day 1

Secondary outcomes (2)
  1. To bridge basic and clinical research

    To integrate preclinical data (Patch-seq, long-read sequencing) with clinical data (microneurography) to accelerate the translation of research into personalised pain management strategies.

    Measured: Day 1

  2. Chronic pain database

    To build a database of 100 patients with neuropathic pain due to small fibre neuropathy using the pre-identified electrophysiological profiles.

    Measured: Day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2026
  2. Study startSep 2026 (estimated)
  3. Primary completionSep 2028 (estimated)
  4. Study completionSep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07740681
Sponsor's protocol ID
370701
Acronym
H-Passion
Status last verified
Jul 2026
First submitted
13 Jul 2026
Last updated
31 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Pain, run by King's College Hospital NHS Trust.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ana Ribeiro, MSc (+447768974020, anaribeiro@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment of molecular and functional mechanisms underlying chronic neuropathic pain (time frame: Day 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in